Dover, United States
Invitris is a pioneering startup in the field of synthetic biology, carving a niche in the development of innovative protein-based drugs. The company's proprietary biotech platform, Phactory, stands out for its 10,000x higher efficiency in designing synthetic proteins and a remarkable 100x reduction in material costs. Leveraging this innovative technology, Invitris is at the forefront of developing the next generation of protein-based drugs, particularly focusing on novel classes of antibiotics.
Founded in 2022 and headquartered in Germany, Invitris recently secured a significant $500.00K Pre Seed Round investment on 05 April 2023, with backing from renowned tech accelerator Y Combinator. With this injection of capital and the trailblazing potential of its technology, Invitris is poised to lead the way in revolutionizing the biopharma, biotechnology, and pharmaceutical industries.
